DE-THE-LYCRA-COMPANY
23.7.2024 11:01:35 CEST | Business Wire | Press release
The LYCRA Company, a global leader in developing innovative and sustainable fiber and technology solutions for the apparel and textile industry, has announced that its COOLMAX® EcoMade fiber made from 100% textile waste is a key ingredient in the Brazilian Volleyball team’s indoor and beach jerseys for the 2024 Summer Games in Paris. Body Work, a fitness brand from retailer Riachuelo, created the official uniforms unveiled in a stunning projection on the Christ the Redeemer statue overlooking Rio de Janeiro on June 27, Volleyball Day in Brazil.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240716778680/en/
Body Work, a fitness brand from Riachuelo, has revealed the official Brazilian Volleyball team shirts for the 2024 Summer Games. The fabric blends two technologies from The LYCRA Company: 92% COOLMAX® EcoMade fiber made from pre-consumer textile waste and 8% LYCRA® fiber to help keep athletes cool, dry, and moving freely. (Photo: Business Wire)
COOLMAX® EcoMade fiber transports moisture away from the body to the surface of the fabric, where it evaporates. This helps athletes stay cool, dry, and comfortable so they can focus on the game. It is one of many innovative branded fibers produced by The LYCRA Company designed to help optimize athletic performance. This technology converts pre-consumer textile waste scraps from garment manufacturers into fibers offering comparable performance to virgin polyester.
“We are thrilled that Brazil’s volleyball uniforms feature 92% COOLMAX® EcoMade fiber made from textile waste and 8% LYCRA® fiber, so we will be rooting for them in Paris,” said Nicolas Banyols, chief commercial officer - apparel, The LYCRA Company. “The benefits of activewear and sportswear with performance fibers are not limited to elite athletes anymore. Consumers of all abilities can now buy these innovative garments at retail, ensuring that everyone can experience the enhanced comfort and performance our fibers offer, in addition to options for durable and sustainable fibers for reduced environmental impact.”
LYCRA® brand fibers, now owned by The LYCRA Company, have been an integral part of the games since 1968, when the French alpine ski team dominated the medal count in Grenoble. The team's ski suits featured LYCRA® fiber, which provided a second-skin fit and greater freedom of movement. The long-standing history of performance and innovation in sports is a testament to the trust and reliability that the company’s fibers offer, instilling confidence in athletes and consumers alike.
“While the silver medal-winning 1984 Brazilian volleyball team uniform was the main inspiration for the design of this jersey, we wanted the fabric to be cutting-edge and future-focused,” said Camila de Paula Souza, Style Manager at Body Work | Riachuelo. “This fabric is designed to provide comfort and is made from textile waste—a win for athletes and a win for the planet.”
Consumers may purchase the official Brazilian Volleyball Team shirts at riachuleo.com. For more information on COOLMAX® EcoMade fiber benefits, visit coolmax.com.
About The LYCRA Company
The LYCRA Company is a leading global fiber and technology solutions provider to the apparel and personal care industries committed to offering sustainable products using renewable, pre-, and post-consumer recycled ingredients that reduce waste and help set the stage for circularity. Headquartered in Wilmington, Delaware, United States, it owns the LYCRA®, LYCRA HyFit®, LYCRA® T400®, COOLMAX®, THERMOLITE®, ELASPAN®, SUPPLEX® and TACTEL® brands. The LYCRA Company adds value to its customers’ products by offering unique innovations that meet the consumer’s need for comfort and lasting performance. Learn more at lycra.com.
COOLMAX® and LYCRA® are trademarks of The LYCRA Company.
About Riachuelo
With over 75 years of history, Riachuelo operates with the purpose of connecting desires to achievements. By combining innovation, dynamism, and agility to deliver collections and products for all styles, the brand is a leading reference in the sector and is recognized as one of the largest fashion companies in Brazil. Riachuelo boasts more than 30 million cardholders and over 400 own stores across the country.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240716778680/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom